Effect of Methylphenidate Formulation for Attention Deficit Hyperactivity Disorder on Patterns and Outcomes of  Treatment

Lage, Maureen J.; Hwang, Pieway

doi:10.1089/cap.2004.14.575

Cited by 48 publications

(33 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One caveat of the present study is that the acute effects of immediate-release methylphenidate were tested. Sustained-release formulations of methylphenidate are commonly used to manage the symptoms of ADHD, and, of course, it is administered chronically (e.g., Lage and Hwang 2004). The results of a previous study conducted in our laboratory suggest that the behavioral effects of immediate-release and sustained-release methylphenidate (20 and 40 mg) differ quantitatively .…”

Section: Discussionmentioning

confidence: 82%

Methylphenidate increases cigarette smoking

et al. 2005

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 82%

Methylphenidate increases cigarette smoking

et al. 2005

View full text Add to dashboard Cite

show abstract

“…The clinical and epidemiological literature on this topic is mixed regarding whether or not stimulant medications increase the risk of tobacco smoking in ADHD-diagnosed individuals (Biederman et al 1999;Lambert 2002;Lambert and Hartsough 1998;Loney et al 2002). Second, the acute effects of immediate-release methylphenidate were tested in the current experiment, whereas in a treatment setting, sustained-release formulations are commonly prescribed (e.g., Lage and Hwang 2004). Rate-ofonset has been shown to modulate the behavioral effects of stimulant drugs including methylphenidate and cocaine (Abreu et al 2001;Kollins et al 1998).…”

Section: Discussionmentioning

confidence: 99%

A pharmacological analysis of stimulant-induced increases in smoking

et al. 2007

View full text Add to dashboard Cite

show abstract

“…12,14 This higher rate of treatment continuity with ER-MPH may be related to the simpler dosing regimen in which asingle dose provides clinical effects for about 8h ours compared with IR-MPH, which requires several daily doses to provide coverage throughout the day. 15 In the present study,weevaluated whether ER-MPH formulations areassociated with greater treatment continuity than are IR-MPH formulations in the community management of adults with ADHD under managed care.…”

Section: Continuity In Methylphenidate Treatment Of Adultsmentioning

confidence: 99%

Continuity in Methylphenidate Treatment of Adults With Attention-Deficit/Hyperactivity Disorder

Olfson¹,

Marcus²,

Zhang³

et al. 2007

JMCP

View full text Add to dashboard Cite

ReseaRch Int he general adult population, the prevalence of attentiondeficit/hyperactivity disorder (ADHD) is approximately 2% to 4%. [1][2][3][4] Methylphenidate (MPH) effectively ameliorates many symptoms of adult ADHD. [5][6][7][8][9] In 1l arge 6-week randomized controlled trial of adults with ADHD,7 immediate-release methylphenidate (IR-MPH) was associated with a76% response rate, compared with a1 9% response rate for placebo. In a 6-week trial with the same response criteria, 66% of subjects treated with osmotic release oral system methylphenidate (OROS-MPH) responded, compared with 39% who received placebo. 9In both studies, response was defined as a3 0% symptom reduction and, at least, much overall improvement.Early discontinuation of treatment is common in the community careo fp atients initiating stimulant therapy. [10][11][12][13] In 1s tudy, BACKGROUND: Although stimulant therapyiscommonly discontinued early in adults with attention-deficit/hyperactivity disorder (ADHD), the factors that contribute to continuity of stimulant therapyremain largely unknown.OBJECTIVE: To (1) comparethe continuity of methylphenidate (MPH) therapy among adults who use immediate-release methylphenidate (IR-MPH) for ADHD with adults who use extended-release methylphenidate (ER-MPH) formulations, and (2) RESULTS: Less than one third(30.0%) of the adult patients who were prescribed MPH had 1ormoremedical claims with adiagnosis code for ADHD.For the adult MPH patients with at least 1medical claim with a diagnosis code for ADHD,the patients who initiated therapywith ER-MPH (N =2,833) weresignificantly younger,weremorelikely to be male,and were less likely to be treated by apsychiatrist than werethe patients who initiated therapywith IR-MPH (N =2,289). Only 50.5% (n =1,156) of IR-MPH patients and 61.4% (n =1,739) of ER-MPH patients had morethan 1pharmacyclaim for the indexMPH medication. Adults treated with ER-MPH also had a significantly longer median duration of treatment with the indexmedication (ER-MPH: 68 days, 95% confidence interval [CI], 65-71 days vs. IR-MPH 39 days, 95% CI, 33-52 days). Controlling for group differences in age,gender, treatment by apsychiatrist, recently prescribed psychotropic medications, treated mental disorders, emergencymental health treatment, and inpatient mental health care, ER-MPH initiation wasassociated with an average 27% longer duration of treatment than with IR-MPH (survival time ratio: 1.27, 95% CI, 1.20-1.35).CONCLUSION: In management of adult ADHD,use of ER-MPH formulations wasassociated with alonger median duration of the initially prescribed medication than wasuse of IR-MPH. It is unknown whether the observed absolute unadjusted difference of 29 days in median length of therapyis clinically important.

show abstract

Effect of Methylphenidate Formulation for Attention Deficit Hyperactivity Disorder on Patterns and Outcomes of Treatment

Abstract: These data support the use of XR MPH with its simplified dosing regimen for children with ADHD.

Cited by 48 publications

References 11 publications

Methylphenidate increases cigarette smoking

Methylphenidate increases cigarette smoking

A pharmacological analysis of stimulant-induced increases in smoking

Continuity in Methylphenidate Treatment of Adults With Attention-Deficit/Hyperactivity Disorder

Contact Info

Product

Resources

About